We continue to forecast solid low-to-mid-teens sales growth and high-teens earnings per share growth throughout fiscal 2001 despite the crippling effects of the (weak) euro.

210

Overall, we believe that the earnings outlook for Medtronic is the strongest in the industry, and Medtronic remains the one company that we have the most confidence in with respect to delivering on its earnings guidance.

206

What is disappointing is that Abbott took a very aggressive approach with this drug, ... They clearly made a poor decision.

159

We hope to learn more about the status of the FDA letter on Tuesday.

90